Live Chat ×
Skip to main content

Hot Topics Symposium - 2016 Annual Meeting Recording

OVERVIEW
The ROSE trial has just been completed, and this symposium presents two talks offering the first comprehensive review of this study, which compared stereotactic radiation and open surgery for treatment of drug resistant temporal lobe epilepsy. As the recent additions of several new drugs to treat epilepsy adds further complexity of choosing appropriate therapy, this symposium will review how these agents should be incorporated into clinical practice, discussing efficacy, side effects, cost effectiveness and mechanisms of action. The final talk will review new personal monitoring apps developed for patients to track, detect and manage seizures. These apps are gaining widespread use and offer new opportunities for managing seizures. 

LEARNING OBJECTIVES
Following participation in this symposium, learners should be able to:

  • Discuss the use of stereotactic radiation for treatment of drug resistant temporal lobe epilepsy and advise patients regarding treatment options.
  • Discuss the use of new anticonvulsant medications and better plan antiepileptic drug therapy.
  • Describe various apps available on smartphones and other portable electronic devices and advise patients on the use of these apps.

TARGET AUDIENCE
Intermediate and Advanced

PROGRAM
Chair: Michael Sperling, M.D.

Introduction
Michael Sperling, M.D.

ROSE (Radiosurgery or Open Surgery for Epilepsy) Trial: Efficacy and Adverse Events
Nicholas Barbaro, M.D.

ROSE (Radiosurgery or Open Surgery for Epilepsy) Trial: Efficacy and Adverse Events: Secondary Outcomes and Health Care Utilization
Mark Quigg, M.D.

How Should Recently Approved Antiepileptic Drugs Be Incorporated into Clinical Practice?
Elinor Ben-Menachem, M.D., Ph.D.

Seizure Apps and Non-EEG Seizure Detection
Gregory Krauss, M.D.

Conclusions
Michael Sperling, M.D.

COMMERCIAL SUPPORT ACKNOWLEDGEMENT
Supported in part by an educational grant from UCB, Inc.

Attendees of the 2016 Annual Meeting have free access to recordings.